GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Results] 38 weeks, 6kg, and satiety was the hard part — 61 comments in the full submission. View in context.
702
c/cagrilintide·submitted 1 year ago by u/noor_vermeulen

[Results] 38 weeks, 6kg, and satiety was the hard part

Labbranch of 7 comments

38 weeks, 6kg, and satiety was the hard part. Posting the boring middle of the process, because the internet is full of the start and the end and nothing else. Pulling the figures out of the title: 38 weeks and 6kg. All of it is written down as it happened rather than reconstructed. The tolerability tables were more…

Read the full submission and all 61 comments →

This branch

7 comments, started 1 year ago
u/lucia_bruun-35 points·1 year ago

What does the tolerability table in that paper actually say?

replysharereportpermalink
u/liv_kuipers1 point·1 year ago

What does the tolerability table in that paper actually say?

Adding the standing caveat — nothing here is approved standalone and research material is not for human use.

replysharereportpermalink
u/lucia_bruun1 point·1 year ago

Dosing intuitions from the GLP-1 boards do not transfer. Different receptor family, different exposure-response, and no published schedule for members to reason from.

replysharereportpermalink
u/mateusz_adebayo1 point·1 year ago

Yes. The combination is where the interesting effect sizes are, and the monotherapy arms read very differently.

replysharereportpermalink
u/rania_marchand1 point·1 year ago

this is a less-travelled board and the evidence base shows it

replysharereportpermalink
u/clara_weiss1 point·1 year ago

the co-agonism argument is about complementary mechanisms

replysharereportpermalink
u/incretin_ivypharmacology1 point·1 year ago

nothing here is approved as a standalone product and research material is not for human use

replysharereportpermalink

← back to the whole thread

About c/cagrilintide

Amylin analog pharmacology and the CagriSema combination: why amylin and GLP-1 co-agonism produces a different satiety profile, the REDEFINE readouts, and the very limited pool of people handling cagrilintide as research material.

19kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
c/cagrilintide rules
  1. Amylin is not a GLP-1. Posts conflating them get corrected.
  2. CagriSema ratios in trials are fixed-dose. Do not extrapolate to self-mixing.
  3. Not approved anywhere. Keep posts descriptive, not instructional.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.